BioNTech SE (NASDAQ:BNTX) to Post Q3 2024 Earnings of $0.85 Per Share, HC Wainwright Forecasts

BioNTech SE (NASDAQ:BNTX) – Equities researchers at HC Wainwright upped their Q3 2024 earnings estimates for BioNTech in a note issued to investors on Monday, August 19th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of $0.85 per share for the quarter, up from their previous forecast of $0.81. HC Wainwright currently has a “Buy” rating and a $113.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($2.04) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.62 EPS, Q3 2025 earnings at $0.82 EPS and Q4 2025 earnings at $0.79 EPS.

A number of other research firms have also weighed in on BNTX. Evercore ISI initiated coverage on shares of BioNTech in a report on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price on the stock. TD Cowen lowered their price objective on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. decreased their target price on BioNTech from $94.00 to $91.00 and set an “underweight” rating on the stock in a research note on Thursday, August 15th. Finally, Deutsche Bank Aktiengesellschaft upgraded BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $109.09.

BioNTech Trading Up 0.5 %

Shares of BioNTech stock opened at $88.99 on Tuesday. The company’s 50-day moving average price is $84.14 and its 200-day moving average price is $89.62. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $76.53 and a 12-month high of $125.83. The company has a market cap of $21.16 billion, a price-to-earnings ratio of 177.98 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The company had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. During the same quarter in the prior year, the company earned ($0.86) EPS. The company’s revenue was down 23.3% on a year-over-year basis.

Institutional Investors Weigh In On BioNTech

Large investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp boosted its holdings in shares of BioNTech by 326.3% during the fourth quarter. Mackenzie Financial Corp now owns 21,874 shares of the company’s stock worth $2,303,000 after purchasing an additional 16,743 shares during the period. abrdn plc bought a new stake in shares of BioNTech in the 4th quarter worth approximately $10,961,000. CWM LLC increased its stake in shares of BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after buying an additional 217 shares during the period. Marks Group Wealth Management Inc bought a new position in shares of BioNTech during the fourth quarter valued at approximately $405,000. Finally, Truist Financial Corp bought a new position in shares of BioNTech during the fourth quarter valued at approximately $1,445,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.